Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

Table 1 Changes in bone mineral density in the ARBI, ARIBON and SABRE trials

		Percentage change in BMD at 2 years^b
		Lumbar spine				Hip
Study (accrual)	Osteoclast inhibitor^a	Low risk	Intermediate risk on no bisphosphonate	Intermediate risk on bisphosphonate ( P value)	High risk	Low risk	Intermediate risk on no bisphosphonate	Intermediate risk on bisphosphonate ( P value)	High risk
ARBI [1] (n = 213)	Risedronate 35 mg weekly	(-) 2.5	(-) 1.5	(+) 5.7 (0.006)	(+) 6.6	(-) 5.7	(-) 3.9	(+) 1.6 (0.037)	(-) 1.9
ARIBON [2] (n = 131)	Ibandronate 150 mg monthly	(-) 4.79	(-) 3.22	(+) 2.98 (<0.01)	(+) 3.52	(-) 3.72	(-) 3.90	(+) 0.60 (<0.01)	(+) 2.49
SABRE [3] (n = 234)	Risedronate 35 mg weekly	(-) 2.1	(-) 1.8	(+) 2.2 (<0.0001)	(+) 3.0	(-) 0.4	(-) 1.1	(+) 1.8 (<0.0001)	(+) 2.0

Percentage change in bone mineral density (BMD) from baseline in postmenopausal women with early-stage breast cancer receiving adjuvant anastrozole with or without oral bisphosphonate therapy. ^aAll patients received calcium + vitamin D. ^bLow risk, study arm that is at low risk of osteoporotic fracture (anastrozole alone); intermediate risk, study arm that is at intermediate risk for osteoporotic fracture (anastrozole with bisphosphonate or not); high risk, study arm that is at higher risk for osteoporotic fracture (anastrozole and bisphosphonate). (+), increase; (-), decrease.

ISSN: 1465-542X